Volume : VI, Issue : II, February - 2016

Topotecan Induces Spermatotoxicity An In Vivo Study

Sujayraj R. S. , Prashantha Naik, Vishma B. L. , Guruprasad Kalthur

Abstract :

<p>Topotecan (TPT), an anticancer drug has been evaluated for its spermatotoxicity. Four doses of TPT, viz., 0.25, 0.5, 0.75 and 1.0 mg/kg were administered i.p. to Swiss albino mice and 35–days’ post–treatment sampling was performed for sperm abnormality, motility, count and gonadosomatic index (GSI). TPT at 0.5 mg/kg onwards induced reproductive toxicity as indicated by the dose–dependent significant increase in the frequency of abnormal sperm accompanied with the decrease in the motility and count. At higher doses of TPT (0.75 and 1.0 mg/kg), there was also a significant reduction in the GSI compared with the solvent control (P<0.05). However, it was not a dose–dependent, indicating that there is no direct correlation between GSI and spermatotoxicity. Thus, TPT treatment needs to be taken care giving the priority to prevent/minimize reproductive toxicity, particularly in case of post–pubertal cancer patients. Various possible mechanisms of TPT–induced spermatotoxicity are discussed.  </p>

Keywords :

Article: Download PDF   DOI : 10.36106/ijar  

Cite This Article:

Sujayraj R. S., Prashantha Naik, Vishma B.L, Guruprasad Kalthur Topotecan Induces Spermatotoxicity – An In Vivo Study Indian Journal of Applied Research, Vol.6, Issue : 2 February 2016

Number of Downloads : 713

References :

<p><p><p><p><pre></pre></p></p></p></p>